Dry eye is an ocular disease caused due to insufficiency or lack of tears in eye. Tears made up of three layers viz. lipids, mucin and aqueous keep eye moist and lubricated. Lack of tears lead to redness, burning, sensing and pain in eye. Dry eye disease also known as Keratoconjuctivitis Sicca is a common phenomenon, which is estimated to have prevalence of 8% to 34% across the globe. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye disease. Dry eye is a multifactorial disease, most of the currently approved prescription and currently approved dry eye treatment products are targeted to relief the signs and symptoms of dry eye disease. The choice of treatment depends upon the type and severity of dry eye disease.
The growing array of imaging modalities to shed light on the pathophysiology of dry eye market. This is
one of the prominent trends on the back of which the dry eye disease market evolved steadily. The
substantial prevalence of dry eye disease (DED) and its growing prevalence among women and aging
populations has made the disease a considerable health burden. This has propelled investments in the
diagnosis and management of DED. Resultantly, the dry eye diseases market has seen a slew of
investments in research and development of novel drugs.
Request a PDF Sample -
Top players are engaging in licensing agreements and pinning hopes on tactical collaborations to
consolidate their positions in the dry eye disease market. In recent years, blockbuster drugs have
Some of the prominent companies in the dry eye diseases market are Johnson & Johnson, Sun
Pharmaceutical Industries Ltd., Allergan plc, Novartis AG, and Santen Pharmaceutical Co.
Large Strides Made In Diagnostic Modalities Underpin New Avenues for Growth
Among the various regions, the drug pipeline is markedly robust in North America. In fact, the region
held a leading share in the global dry eye disease market in 2016. Rising uptake of prescription eyedrops
among the patient populations and large strides made in diagnostic modalities have helped the region
to occupy a prominent position. In this regard, advancement in mechanism of cyclosporine eye drops.
The regional market will continue to do so in coming few years. Growing body of clinical studies and
research in ocular surface health has further augmented the prospects in this key market.
Expanding array of anti-inflammatory drugs have kept the drug pipeline rich in the dry eye disease
market. Moreover, the loss of productivity due to DED is propelling interest of global health systems in
their management, especially in developed nations. Further, advances in diagnostic modalities h